10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2014 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 24, 2015) | |||
(In Thousands, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
Operating activities | |||
Net income | $ 2,569,700 | 2,489,700 | 2,655,500 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Net realized gains on investments | (177,000) | (271,900) | (334,900) |
Other-than-temporary impairment losses recognized in income | 49,000 | 98,900 | 37,800 |
Loss on extinguishment of debt | 81,100 | 145,300 | 0 |
(Gain) loss on disposal from discontinued operations | (3,200) | 221,800 | 0 |
(Gain) loss on disposal of assets | (1,700) | 3,900 | 4,700 |
Deferred income taxes | 30,700 | 59,100 | 127,500 |
Amortization, net of accretion | 744,500 | 800,900 | 633,600 |
Depreciation expense | 106,500 | 107,900 | 107,100 |
Impairment of property and equipment | 7,900 | 47,700 | 66,800 |
Share-based compensation | 168,900 | 146,000 | 146,500 |
Excess tax benefits from share-based compensation | (46,400) | (30,100) | (28,800) |
Changes in operating assets and liabilities: | |||
Receivables, net | (1,899,700) | (418,300) | 189,900 |
Other invested assets | (21,700) | (15,100) | (38,900) |
Other assets | 405,500 | (33,600) | 79,200 |
Policy liabilities | 1,240,600 | (345,800) | (53,700) |
Unearned income | 255,100 | (73,800) | (193,700) |
Accounts payable and accrued expenses | (14,400) | 303,600 | (406,500) |
Other liabilities | (7,900) | (154,600) | (132,800) |
Income taxes | (34,000) | 9,300 | (73,900) |
Other, net | (84,200) | (38,600) | (40,800) |
Net cash provided by operating activities | 3,369,300 | 3,052,300 | 2,744,600 |
Investing activities | |||
Purchases of fixed maturity securities | (9,613,400) | (13,704,500) | (15,040,400) |
Proceeds from fixed maturity securities: | |||
Sales | 8,066,000 | 10,977,900 | 13,675,900 |
Maturities, calls and redemptions | 1,318,700 | 1,836,800 | 1,781,500 |
Purchases of equity securities | (912,000) | (820,300) | (232,800) |
Proceeds from sales of equity securities | 746,500 | 721,000 | 422,700 |
Purchases of other invested assets | (205,700) | (251,500) | (303,700) |
Proceeds from sales of other invested assets | 124,700 | 127,100 | 35,500 |
Settlement of non-hedging derivatives | (67,400) | (109,800) | (59,800) |
Changes in securities lending collateral | (545,600) | (405,100) | 307,900 |
Purchases of subsidiaries, net of cash acquired | 0 | 0 | (4,597,000) |
Proceeds from sale of subsidiary, net of cash sold | 740,000 | 0 | 0 |
Purchases of property and equipment | (714,600) | (646,500) | (544,900) |
Proceeds from sales of property and equipment | 88,000 | 39,200 | 400 |
Other, net | (100) | 1,300 | 3,100 |
Net cash used in investing activities | (974,900) | (2,234,400) | (4,551,600) |
Financing activities | |||
Net repayments of commercial paper borrowings | (379,200) | (191,700) | (229,000) |
Proceeds from long-term borrowings | 2,700,000 | 1,250,000 | 6,468,900 |
Repayments of long-term borrowings | (1,730,100) | (1,801,900) | (1,251,300) |
Proceeds from short-term borrowings | 2,050,000 | 1,100,000 | 642,000 |
Repayments of short-term borrowings | (2,050,000) | (950,000) | (492,000) |
Changes in securities lending payable | 545,600 | 405,000 | (307,800) |
Changes in bank overdrafts | 173,000 | 9,900 | (17,600) |
Premiums paid on equity options | 0 | (25,800) | 0 |
Repurchase and retirement of common stock | (2,998,800) | (1,620,100) | (2,496,800) |
Cash dividends | (480,700) | (448,000) | (367,100) |
Proceeds from issuance of common stock under employee stock plans | 301,300 | 524,700 | 110,800 |
Excess tax benefits from share-based compensation | 46,400 | 30,100 | 28,800 |
Net cash (used in) provided by financing activities | (1,822,500) | (1,717,800) | 2,088,900 |
Effect of foreign exchange rates on cash and cash equivalents | (7,100) | 2,200 | 1,100 |
Change in cash and cash equivalents | 564,800 | (897,700) | 283,000 |
Cash and cash equivalents at beginning of year | 1,586,900 | 2,484,600 | |
Cash and cash equivalents at end of year | 2,151,700 | 1,586,900 | 2,484,600 |
Less cash and cash equivalents of discontinued operations at end of year | 0 | (4,800) | (9,300) |
Cash and cash equivalents of continuing operations at end of year | 2,151,700 | 1,582,100 | 2,475,300 |
External Links | |
ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2014 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |